Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Hormone. Texas Oncology and US Oncology Research, Webster, TX, United States



Survival: 17.8 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
Hormone
   
Drugs:
Country: United States
   
City/State/Province: Webster, TX
   
Hospital: Texas Oncology and US Oncology Research
   
Journal: Link
   
Date: 11/2011

Description:
Patients:
This phase II study involved men with metastatic castration-resistant prostate cancer who were separated into two separate treatment groups. Group A had 110 patients with a median age of 69.0 years. Group B also had 110 patients with a median age of 69.5 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel, the hormone prednisone, and the biologic therapy agent AT-101, which inhibits a protein, Bcl-2, that prevents cell death.

Patients in group B were treated with the chemotherapy agent docetaxel and the hormone prednisone.

Toxicities:
The most severe adverse events in group A were of grade 4, including neutropenia, pulmonary embolism, fatigue, and anemia.

The most severe adverse events in group B were of grade 4, including neutropenia, deep vein thrombosis, and leucopenia.

Results:
The median overall survival rates for groups A and B were 18.1 and 17.8 months, respectively.

Support:
This study was supported by Ascenta Therapeutics.

Correspondence: Dr. G. Sonpavde; email: guru.sonpavde@usoncology.com

E-mail to a Friend Email Physician More Information